Cargando…
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosin...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Future Medicine Ltd
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571544/ https://www.ncbi.nlm.nih.gov/pubmed/31244990 http://dx.doi.org/10.2217/hep-2019-0001 |